Company Overview and News

 
KLCI seen extending consolidation, firm crude oil price to offer respite

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
KLCI seen extending consolidation, firm crude oil to offer respite

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
Sapura Energy, ECM Libra, Hai-O, Velesto, Maxwell, Deleum, Pestech, OpenSys, Sumatec, KUB, V.S. Industry, Ann Joo, Maybulk, Tan Chong Motor and Warisan TC Holdings

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 26) may include: Sapura Energy Bhd, ECM Libra Financial Group Bhd, Hai-O Enterprise Bhd, Velesto Energy Bhd, Maxwell International Holdings Bhd, Deleum Bhd, Pestech International Bhd, OpenSys (M) Bhd, Sumatec Resources Bhd, KUB Malaysia Bhd, V.S. Industry Bhd, Ann Joo Resources Bhd, Malayan Bulk Carriers Bhd (Maybulk), Tan Chong Motor Holdings Bhd and Warisan TC Holdings Bhd
PBLOF 6874 1295 2143 5189 1201 5016 6556 7668 5219 4405 BSMAF 1818

 
Tan Chong Motor ventures into property investments via stake buy in Warisan TC unit

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Tan Chong Motor Holdings Bhd (TCMH) is taking up a 24.5% stake in Comit Communication Technologies (M) Sdn Bhd (CCT), which owns a piece of leasehold industrial land in Seksyen 13, Petaling Jaya, Selangor from Warisan TC Holdings Bhd for RM13.24 million cash.
5016 4405 BSMAF 1818

 
Econpile, Apex Healthcare, Carlsberg, Daibochi, Dialog, Hock Seng Lee, KPJ, Sarawak Plantation, SunCon and Warisan TC

2018-08-16 theedgemarkets
KUALA LUMPUR (Aug 16): Based on corporate announcements and news flow today, stocks in focus tomorrow may include the following: Econpile Holdings Bhd, Apex Healthcare Bhd, Carlsberg Brewery Malaysia Bhd, Daibochi Bhd, Dialog Group Bhd, Hock Seng Lee Bhd, KPJ Healthcare Bhd, Sarawak Plantation Bhd, Sunway Construction Group Bhd and Warisan TC Holdings Bhd. Econpile Holdings Bhd secured a contract worth RM30.
APEXF KPJHF 5016 7090 6238 5878 5253 5263 2836 5135 7277

 
Warisan TC's 2Q earnings more than double, declares 1 sen dividend

2018-08-16 theedgemarkets
KUALA LUMPUR (Aug 16): Warisan TC Holdings Bhd saw its net profit for the second quarter ended June 30, 2018 (2QFY18) more than double to RM1.77 million or 2.72 sen per share from RM839,000 or 1.29 sen per share a year ago, primarily due to higher revenue from its machinery division and improvement in the automotive business's overall gross profit margin.
5016 BSMAF 1818

 
KLCI rises 0.43% as index-linked blue chips lift

2018-08-07 theedgemarkets
KUALA LUMPUR (Aug 7): The FBM KLCI rose 0.43% at the midday break today as index-linked blue chip stocks lifted the local benchmark index.
HLFBF 7062 7052 7060 7036 1082 5681 BATS 4162 5014 6033 4634 1783 5029 PNADF 5347 5016 1589 SGPBY TNABY 2739 MYPRY TNABF PNAGF

 
Tan Chong Motor, Utusan, Versatile Creative, Pantech, TMC Life, Pavilion REIT, ViTrox, Ajiya, Ancom and Tasek Corp

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): Based on corporate announcements and news flow today, companies that may be in focus on Friday (July 27) may include the following: Tan Chong Motor Holdings Bhd, Utusan Melayu (Malaysia) Bhd, Versatile Creative, Pantech Group Holdings Bhd, TMC Life Sciences Bhd, Pavilion Real Estate Investment Trust, ViTrox Corp Bhd, Ajiya Bhd, Ancom Bhd and Tasek Corp Bhd
5754 4995 0101 5016 4405 5125 BSMAF 5212 1818

 
Tan Chong forms JV in New York to distribute exports from Southeast Asia

2018-07-26 theedgemarkets
KUALA LUMPUR (July 26): Tan Chong Motor Holdings Bhd today announced the formation of a joint venture (JV) company in New York to allow the group to develop new distribution channels in the United States and Canada for exports from Southeast Asia.
5016 4405 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...